Resveratrol increases cerebral glycogen synthase kinase phosphorylation as well as protein levels of drebrin and transthyretin in mice: An exploratory study

International Journal of Food Sciences and Nutrition

Volumn 65, Issue 1, 2014, Pages 89-96

  Varamini, Behzad ^a   Sikalidis, Angelos K ^a,b   Bradford, Kathryn L ^a  

^a Department of Obstetrics Gynecology   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

amyloid; Alzheimer's disease; Drebrin; Glycogen synthase kinase 3 ; Neurodegeneration; Resveratrol; Tau; Transthyretin

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CHIMERIC PROTEIN; DREBRINS; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; NERVE PROTEIN; NEUROPEPTIDE; NEUROPROTECTIVE AGENT; PREALBUMIN; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; RECOMBINANT PROTEIN; RESVERATROL; STILBENE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; BRAIN; DIET SUPPLEMENTATION; DIET THERAPY; DRUG ANTAGONISM; DRUG POTENTIATION; ENZYMOLOGY; GENETICS; GERMFREE ANIMAL; HUMAN; MALE; METABOLISM; MOUSE; MUTATION; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CEREBRUM; DIETARY SUPPLEMENTS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MICE; MICE, TRANSGENIC; MUTANT CHIMERIC PROTEINS; MUTATION; NERVE TISSUE PROTEINS; NEURONS; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; PREALBUMIN; PRESENILIN-1; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; STILBENES;

EID: 84892715064     PISSN: 09637486     EISSN: 14653478     Source Type: Journal    
DOI: 10.3109/09637486.2013.832171     Document Type: Article

References (67)

1. Albani D, Polito L, Forloni G. 2010. Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J Alzheimers Dis 19:11-26.
2. Anekonda TS, Reddy PH. 2006. Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem 96:305-313.
3. Avila J, Wandosell F, Hernández F. 2010. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert Rev Neurother 10:703-710.
4. Barger JL, Kayo T, Vann JM, Arias EB, Wang J, Hacker TA, Wang Y, et al. 2008. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 3:e2264.
5. Basil A, Soulet S, Chaher N, Mérillon JM, Chibane M, Monti JP, Richard T. 2012. Wine polyphenols: potential agents in neuroprotection. Oxid Med Cell Longev 2012:805762.
6. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Karla A, Prabhu VV, et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337-342.
7. Benitez DA, Pozo-Guisado E, Clementi M, Castellón E, Fernandez-Salguero PM. 2007. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway. Br J Cancer 96:1595-1604.
8. Bertram L, Tanzi RE. 2008. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 9: 768-778.
9. Bilb M, Esselmann H, Wiltfang J. 2012. Neurochemical biomarkers in Alzheimer's disease and related disorders. Ther Adv Neurol Disord 5: 335-348.
10. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. 2004. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101:2173-2178.
11. Cecchinato V, Chiaramonte R, Nizzardo M, Cristofaro B, Basile A, Sharbet GV, Comi P. 2007. Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem Pharmacol 74:1568-1574.
12. Counts SE, He B, Nadeem M, Wuu J, Scheff SW, Mufson EJ. 2012. Hippocampal drebrin loss in mild cognitive impairment. Neurodegener Dis 10:216-219.
13. Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ. 2006. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol 65:592-601.
14. Dasgupta B, Milbrandt J. 2007. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 104:7217-7222.
15. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. 1999. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58:376-388.
16. de Oliveira RM, Pais TF, Outeiro TF. 2010. Sirtuins: common targets in aging and in neurodegeneration. Curr Drug Targets 11:1270-1280.
17. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, et al. 2002. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 59:398-407.
18. Diomede L, Rigacci S, Romeo M, Stefani M, Salmona M. 2013. Oleuropein aglycone protects transgenic C. elegans strains expressing Ab42 by reducing plaque load and motor deficit. PLoS One 8:e58893.
19. Dun XP, Bandeira de Lima T, Allen J, Geraldo S, Gordon-Weeks P, Chilton JK. 2012. Drebrin controls neuronal migration through the formation and alignment of the leading process. Mol Cell Neurosci 49: 341-350.
20. Dun XP, Chilton JK. 2010. Control of cell shape and plasticity during development and disease by the actin-binding protein Drebrin. Histol Histopathol 25:533-540.
21. Filippi-Chiela EC, Villodre ES, Zamin LL, Lenz G. 2011. Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells. PLoS One 6:e20849.
22. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, et al. 2006. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24:516-524.
23. Geraldo S, Khanzada UK, Parsons M, Chilton JK, Gordon-Weeks PR. 2008. Targeting of the F-actin-binding protein drebrin by the microtubule plus-tip protein EB3 is required for neuritogenesis. Nat Cell Biol 10:1181-1189.
24. Guerreiro RJ, Gustafson DR, Hardy J. 2012. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging 33:437-456.
25. Han YS, Bastianetto S, Dumont Y, Quirion R. 2006. Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain. J Pharmacol Exp Ther 318:238-245.
26. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, et al. 2008. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216-223.
27. Hooper C, Killick R, Lovestone S. 2008. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104:1433-1439.
28. Howlett DR, Richardson JC. 2009. The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP? Histol Histopathol 24:83-100.
29. Jiang WJ. 2008. Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun 373:341-344.
30. Joseph JA, Denisova NA, Arendash G, Gordon M, Diamond D, Shukitt-Hale B, Morgan D. 2003. Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr Neurosci 6:153-162.
31. Julien C, Tremblay C, Bendjelloul F, Phivilay A, Coulombe MA, Emond V, Calon F. 2008. Decreased drebrin mRNA expression in Alzheimer disease: correlation with tau pathology. J Neurosci Res 86:2292-2302.
32. Kaeberlein M. 2013. Longevity and aging. F1000Prime Rep 5:5.
33. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. 2009. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 54: 111-118.
34. Kawas CH. 2006. Diet and the risk of Alzheimer's disease. Ann Neurol 59:877-879.
35. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, et al. 2007. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26:3169-3179.
36. Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. 2006. Therapeutic approaches to Alzheimer's disease. Brain 129:2840-2855.
37. Klinge CM, Blankenship KA, Risinger KE, Bhatnagar S, Noisin EL, Sumanasekera WK, Zhao L, et al. 2005. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J Biol Chem 280:7460-7468.
38. Kojima N, Shirao T. 2007. Synaptic dysfunction and disruption of postsynaptic drebrin-actin complex: a study of neurological disorders accompanied by cognitive deficits. Neurosci Res 58:1-5.
39. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, et al. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109-1122.
40. Leduc V, Jasmin-Bélanger S, Poirier J. 2010. APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol Med 16:469-477.
41. Leroy K, Yilmaz Z, Brion JP. 2007. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 33:43-55.
42. Li F, Gong Q, Dong H, Shi J. 2012. Resveratrol, a neuroprotective supplement for Alzheimer's disease. Curr Pharm Des 18:27-33.
43. Lin H, Xiong W, Zhang X, Liu B, Zhang W, Cheng J, Huang H. 2011. Notch-1 activation-dependent p53 restoration contributes to resveratrol-induced apoptosis in glioblastoma cells. Oncol Rep 26:925-930.
44. Liu F, Iqbal K, Grundke-Iqbal I, Gong CX. 2002. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett 530:209-214.
45. Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, Zhang M, et al. 2013. Inhibition of GSK3b-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 123:224-235.
46. Marambaud P, Zhao H, Davies P. 2005. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 280: 37377-37382.
47. Miyamoto E. 2006. Molecular mechanism of neuronal plasticity: induction and maintenance of long-term potentiation in the hippocampus. J Pharmacol 100:433-442.
48. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, Néri C. 2005. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37: 349-350.
49. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF. 1999. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58:1010-1019.
50. Poirier J. 2003. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 9: 94-101.
51. Reixach N, Adamski-Werner SL, Kelly JW, Koziol J, Buxbaum JN. 2006. Cell based screening of inhibitors of transthyretin aggregation. Biochem Biophys Res Commun 348:889-897.
52. Ribeiro CA, Saraiva MJ, Cardoso I. 2012. Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide-relevance in Alzheimer's disease. PLoS One 7:e45368.
53. Rocha-González HI, Ambriz-Tututi M, Granados-Soto V. 2008. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci Therapeutics 14:234-247.
54. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, et al. 2005. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to betaamyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18:602-617.
55. Schreiber G. 2002. The evolution of transthyretin synthesis in the choroid plexus. Clin Chem Lab Med 40:1200-1210.
56. Sgarbossa A. 2012. Natural biomolecules and protein aggregation: emerging strategies against amyloidogenesis. Int J Mol Sci 13: 17121-17137.
57. Shim KS, Lubec G. 2002. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci Lett 324:209-212.
58. Sikalidis AK, Stipanuk MH. 2010. Growing rats respond to a sulfur amino acid-deficient diet by phosphorylation of the a subunit of eukaryotic initiation factor 2 heterotrimeric complex and induction of adaptive components of the integrated stress response. J Nutr 140:1080-1085.
59. Singh TJ, Haque N, Grundke-Iqbal I, Iqbal K. 1995. Rapid Alzheimerlike phosphorylation of tau by the synergistic actions of non-prolinedependent protein kinases and GSK-3. FEBS Lett 358:267-272.
60. Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, Pilotto A. 2011. Diet and Alzheimer's disease risk factors or prevention: the current evidence. Expert Rev Neurother 11:677-708.
61. Taubenfeld SM, Mileki MH, Monti B, Alberini CM. 2001. The consolidation of new but not reactivated memory requires hippocampal C/EBPbeta. Nat Neurosci 4:813-818.
62. Tsuzuki K, Fukatsu R, Yamaguchi H, Tateno M, Imai K, Fujii N, Yamauchi T. 2000. Transthyretin binds amyloid beta peptides, Abeta1-42 and Abeta1-40 to form complex in the autopsied human kidney-possible role of transthyretin for abeta sequestration. Neurosci Lett 281:171-174.
63. van Marum RJ. 2008. Current and future therapy in Alzheimer's disease. Fundam Clin Pharmacol 22:265-274.
64. Wada A. 2009. GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics. Front Biosci 14:1558-1570.
65. Wang H, Brown J, Marfin M. 2011. Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine 53: 130-140.
66. Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein DL, Thiyagarajan M, et al. 2006. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J 20:2313-2320.
67. Zhang H, Schools GP, Lei T, Wang W, Kimelberg HK, Zhou M. 2008. Resveratrol attenuates early pyramidal neuron excitability impairment and death in acute rat hippocampal slices caused by oxygen-glucose deprivation. Exp Neurol 212:44-52.